Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

• ClinicalTrials.gov Identifier: NCT01844765
• Recruitment Status: Completed
• First Posted: May 1, 2013
• Results First Posted: May 21, 2018
• Last Update Posted: April 22, 2021
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+ chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).

Condition or disease	Intervention/treatment	Phase
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia	Drug: nilotinib	Phase 2

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Detailed Description:

The study was designed as a multi-center, open-label, non-controlled phase II study to assess efficacy, safety and PK parameters of 230 mg/m2 twice daily nilotinib in pediatric patients (1 to <18 years old). The study population consisted of three cohorts of Ph+ CML pediatric patients:

• Cohort 1: Ph+ CML-CP patients resistant or intolerant to either imatinib or dasatinib
• Cohort 2: Ph+ CML-AP patients resistant or intolerant to either imatinib or dasatinib
• Cohort 3: Newly-diagnosed Ph+ CML-CP patients in first chronic phase A minimum number of 50 pediatric patients (from 1 to <18 years) were enrolled in the study. Of them, at least 15 patients were Ph+ CML-CP patients resistant or intolerant to either imatinib or dasatinib, and at least 15 were newly-diagnosed Ph+ CML-CP patients in first chronic phase patients. There was no minimum number of patients required for Ph+ CML-AP patients resistant or intolerant to either imatinib or dasatinib.

Based on enrollment forecasts as of Jan 2015, and to reflect the agreements with the US FDA and the PDCO, the study remained open for enrollment until the targeted number of 50 patients with at least 15 newly diagnosed Ph+CML patients was achieved or until 31May2015, whichever was later.

Patients who completed the study were treated with nilotinib for a total of 66 cycles of 28 days unless the patient prematurely discontinued study treatment.

The primary analysis cut-off date was the date when all patients enrolled in the trial either completed their visit for treatment cycle 12 or had discontinued study treatment early (EoT/early discontinuation visit). These analyses were reported in the 12-cycle clinical study report (CSR). A 24-cycle analysis was done when all patients had either completed their 24-cycle treatment visit or had discontinued study treatment early.

At trial end, a final comprehensive CSR of all data collected during the trial was produced.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 59 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib
• Actual Study Start Date: August 20, 2013
• Actual Primary Completion Date: June 1, 2016
• Actual Study Completion Date: August 28, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: Newly diagnosed and untreated Ph+ CML in first CP; Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.	Drug: nilotinib; Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).; Other Name: AMN107
Experimental: Resistant/intolerant Ph+ CML in CP; Resistant or Intolerant to either imatinib or dasatinib	Drug: nilotinib; Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).; Other Name: AMN107
Experimental: Resistant/intolerant Ph+ CML in AP; Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.	Drug: nilotinib; Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered orally at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).; Other Name: AMN107

Outcome Measures

Primary Outcome Measures :

1. Rate of Major Molecular Response (MMR) at 6 Cycles for Ph+ CML CP Patients Resistant or Intolerant to Imatinib or Dasatinib [ Time Frame: 6 cycles ]
   MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR at 6 cycles if the patient met the MMR criteria at the Cycle 6 Visit.
2. MMR Rate by 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients [ Time Frame: 12 cycles ]
   MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. A patient was counted as having MMR by 12 cycles if the patient met the MMR criteria at least once at any time between first study drug intake and Cycle 12 visit included.
3. Rate of Complete Cytogenic Response (CCyR) at 12 Cycles in Newly Diagnosed Ph+ CML-CP Patients [ Time Frame: 12 cycles ]
   Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit.

Secondary Outcome Measures :

1. MMR Rate by Time Points in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib [ Time Frame: By 3, 6, 9 , 12, 24, 36, 48, 66 cycles ( 1 cycle = 28 days) ]
   Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.
2. MMR Rate by Time Points in Newly Diagnosed Ph+ CML-CP Patients [ Time Frame: by 3, 6, 9, 12, 24, 36, 48, 66 cycles (1 cycle = 28 days) ]
   Major molecular response (MMR) was defined as BCR-ABL/ABL % ≤ 0.1% by IS as measured by RQ-PCR, confirmed by duplicate analysis of the same sample.
3. Best BCR-ABL Ratio Categories for Resistant/Intolerant Ph+ CML - Overall [ Time Frame: up to 66 cycles (1 cycle = 28 days) ]
   MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: > 0.0032 to ≤ 0.01% is equal to a log reduction category of >= 4 to <4.5 -log reduction (MR4); BCR-ABL ratio by percentage: <=0.0032% is equal to a log reduction category of >= 4.5-log reduction (MMR4.5)
4. Best BCR-ABL Ratio Categories for Newly Diagnosed Ph+ CML-CP - Overall [ Time Frame: up to 66 cycles (1 cycle = 28 days) ]
   MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR (Real time quantitative polymerase chain reaction). BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL ratio by percentage: > 0.0032 to ≤ 0.01% is equal to a log reduction category of >= 4 to <4.5 -log reduction (MR4); BCR-ABL ratio by percentage: <=0.0032% is equal to a log reduction category of >= 4.5-log reduction (MMR4.5)
5. Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR [ Time Frame: From first dosing to the first MMR within 66 cycles period ]
   Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR.
6. Time to First MMR Among Newly Diagnosed Ph+ CML-CP Patients Who Achieved MMR [ Time Frame: From first dosing to the first MMR within 66 cycles period ]
   Time to MMR is the time from first study drug intake to first major molecular response computed only for participants who achieved MMR.
7. Duration of First MMR Among Patients Who Were Resistant or Intolerant to Either Imatinib or Dasatinib Who Achieved MMR [ Time Frame: from MMR until confirmed loss of MMR (Assessed up to 66 cycles) ]
   Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.
8. Duration of First MMR Among Newly Diagnosed Patients Who Achieved MMR [ Time Frame: from MMR until confirmed loss of MMR (Assessed up to 66 cycles)es) ]
   Duration of MMR is defined as the time between the date of the first MMR and the date of confirmed loss of MMR (i.e. the earliest of confirmed loss of MMR, CML-related death or progression to AP or BC). Participants without loss of MMR were censored at the last molecular assessment date.
9. Best Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall [ Time Frame: up to 66 cycles ]
   • Complete cytogenetic response (CCyR) - 0% Ph+ metaphases
   • Partial cytogenetic response (PCyR) - >0 to 35% Ph+ metaphases
   • Minor cytogenetic response (mCyR) - >35 to 65% Ph+ metaphases
   • Minimal - >65 to 95% Ph+ metaphases
   • None - >95 to 100% Ph+ metaphases
   • Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
10. Best Complete Cytogenetic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients - Overall [ Time Frame: up to 66 cycles ]
    Complete cytogenetic response (CCyR) - 0% Ph+ metaphases No response - >95 to 100% Ph+ metaphases
11. Summary of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients [ Time Frame: From first dosing to the first CCyR up to 66 cycles ]
    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
12. Kaplan-Meier Estimates of Time to First Complete Cytogenic Response (CCyR) in Newly Diagnosed Ph+ CML-CP Patients [ Time Frame: From first dosing to the first CCyR up to 66 cycles ]
    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
13. Kaplan-Meier Estimates of Duration of First Complete Cytogenic Response (CCyR) Among Patients Who Achieved CCyR in Newly Diagnosed Ph+ CML-CP Patients [ Time Frame: From CCyR to loss of CCyR up to 66 cycles ]
    Cytogenetic response is assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow. Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as having CCyR by 6 cycles (respectively 12 cycles) if the patient met the CCyR criteria at least once at any time between first study drug intake and cycle 6 (cycle 12 respectively) visit included.
14. Best Major Cytogenetic Response (MCyR) Rate by Time Point in Newly Diagnosed Ph+ CML Patients [ Time Frame: 6, 12, 18, 24, 36, 48, 66 cycles ]
    Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
15. Summary of Time to First Major Cytogenetic Response (MCyR) Among Patients Who Achieved MCyR in Newly Diagnosed CML-CP Patients [ Time Frame: up to 66 cycles ]
    Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
16. Kaplan-Meier Estimates of Time to First Major Cytogenetic Response (MCyR) in Newly Diagnosed CML-CP Patients [ Time Frame: up to 66 cycles ]
    Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.
17. Best Complete Hematological Response (CHR) by Time Point [ Time Frame: cycle 3, 6, 9, 12, 18, 24, 36, 48, 66 ]

    Complete Hematological Response (CHR) was defined as

    • WBC count <10×109/L
    • platelet count <450×109/L
    • basophils <5%
    • no blasts and promyelocytes in peripheral blood
    • myelocytes+metamyelocytes <5% in peripheral blood
    • no evidence of extramedullary disease, including spleen and liver
    • Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
18. Summary of Time to First Complete Hematological Response (CHR) Among Patients Who Achieved Confirmed CHR in Newly Diagnosed CML-CP Patients [ Time Frame: from first dosing to CHR, UP TO 66 CYCLES ]

    Complete Hematological Response (CHR) was defined as

    • WBC count <10×109/L
    • platelet count <450×109/L
    • basophils <5%
    • no blasts and promyelocytes in peripheral blood
    • myelocytes+metamyelocytes <5% in peripheral blood
    • no evidence of extramedullary disease, including spleen and liver
    • Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
19. Kaplan-Meier Estimates of Time to First Complete Hematological Response (CHR) in Newly Diagnosed CML-CP Patients [ Time Frame: from first dosing to CHR, UP TO 66 CYCLES ]

    Complete Hematological Response (CHR) was defined as

    • WBC count <10×109/L
    • platelet count <450×109/L
    • basophils <5%
    • no blasts and promyelocytes in peripheral blood
    • myelocytes+metamyelocytes <5% in peripheral blood
    • no evidence of extramedullary disease, including spleen and liver
    • Assessment confirmation after at least 4 weeks for newly diagnosed Ph+ CML-CP
20. Time to Disease Progression for Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients - Kaplan-Meier Estimates [ Time Frame: From first dosing to the disease progression within 66 cycles ]
    Time to disease progression is the time from the date of first study drug intake to the date of event defined as the first progression to AP or BC (from CP) or to BC (from AP) or the date of CML-related death occurring on treatment, whichever was earlier.
21. Event Free Survival in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients [ Time Frame: From first dosing to the disease progression or death up to 66 cycles ]
    Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)
22. Event Free Survival in Newly Diagnosed CML-CP Patients [ Time Frame: From first dosing to the disease progression or death up to 66 cycles ]
    Event Free Survival is defined as the time from the date of first study drug intake to the first occurrence of any of the following loss of CHR, loss of MCyR ( PCyR + CCyR), progression to AP/BC (from CP) or to BC (from AP), or death from any cause. (Including events only during treatment)
23. Overall Survival (OS) in Imatinib/Dasatinib Resistant/Intolerant CML-CP - Kaplan-Meier Estimates [ Time Frame: from first dosing to death up to 66 cycles ]
    Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.
24. Overall Survival (OS) in Newly Diagnosed CML-CP Patients [ Time Frame: from first dosing to death up to 66 cycles ]
    Overall survival is defined as the time from the date of first study drug intake to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of their last assessment for patients on study and date of last contact for patients in follow-up.
25. Pharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle [ Time Frame: By 3, 6, 9, 12, 18, 24, 36, 48, 66 cycles ]
    BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR.
26. Pharmacokinetics (PK): Steady State Concentration of Nilotinib in Imatinib/Dasatinib Resistant/Intolerant CML-CP Patients [ Time Frame: Cycle 1 Day 8 ]
    PK was analyzed only when all patients has completed 12 cycles on treatment or discontinued the study treatment early.
27. Pharmacokinetics: Steady State Concentration of Nilotinib in Newly Diagnosed CML-CP Patients [ Time Frame: Cycle 1 Day 8 ]
    PK was analyzed only when all patients has completed 12 cycles of treatment or discontinued the study treatment early.
28. Growth Data: Abnormal Height Standard Deviation Scores (SDS) Changes by Cohort [ Time Frame: from first dosing to 66 cycles ]
    To assess long term effect on growth, development and maturation of nilotinib treatment in pediatric patients with Ph+ CML in participants with both a baseline and post-baseline value.
29. Acceptability (Including Palatability) of Dose Forms Used After First Dose, Cycle 1 and Cycle 12 Study Drug Formulation [ Time Frame: up to Cycle 12 ]

    Acceptability of the study drug was evaluated from a questionnaire completed by patients, with the help from parents or caregivers at visits.

    The Questionnaire to capture patient assessment of palatability (very good to very bad) and acceptability of taking the medication (very easy to very hard to administration).

30. Mutational Assessment of BCR-ABL [ Time Frame: up to 66 cycles ]
    Emerging signs of resistance to nilotinib

Other Outcome Measures:

1. Long Term Effect of Nilotinib on Bone Metabolism [ Time Frame: Cycle 66 ]
   The summary of bone age and Dual-energy X-ray absorptiometry (DEXA) by cohort. Alteration of bone biochemical markers of hand and wrist X-Ray evaluation was observed in bone age standard deviation scores (SDS) and for bone mineral density for DEXA before and after treatment with nilotinib.

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 17 Years (Child)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Key Inclusion Criteria:

• Newly diagnosed and untreated Ph+ CML CP or Ph+ CML CP or AP resistant or intolerant to either imatinib or dasatinib
• Karnofsky ≥ 50% for patients > 10 years of age and Lansky ≥ 50 for patients ≤ 10 years of age
• Adequate renal, hepatic and pancreatic function
• Potassium, magnesium, phosphorus and total calcium values ≥ LLN (lower limit of normal)
• Written informed consent

Key Exclusion Criteria:

• Treatment with strong CYP3A4 inhibitors or inducers
• Use or planned use of any medications that have a known risk or possible risk to prolong the QT interval
• Acute or chronic liver, pancreatic or severe renal disease
• History of pancreatitis or chronic pancreatitis.
• Impaired cardiac function
• No evidence of active graft vs host and <3mo since Stem Cell Transplant
• Total body irradiation (TBI) or craniospinal radiation therapy <6months
• Hypersensitivity to the active ingredient or any of the excipients including lactose.
• the criteria regarding pregnancy and contraception
• Active or systemic bacterial, fungal, or viral infection
• known Hepatitis B, Hepatitis C, or HIV infection

Contacts and Locations

Locations

United States, California

Loma Linda University Cancer Center

Loma Linda, California, United States, 92350

Lucile Salter Packard Children's Hospital at Stanford

Palo Alto, California, United States, 94304

United States, Florida

Nemours Childrens Hospital

Orlando, Florida, United States, 32827

St. Mary's Hospital

West Palm Beach, Florida, United States, 33407

United States, Maryland

Johns Hopkins Oncology Center ORA

Baltimore, Maryland, United States, 21231

United States, North Carolina

UNC Chapel Hill

Chapel Hill, North Carolina, United States, 27599

United States, Ohio

Nationwide Childrens Hospital

Columbus, Ohio, United States, 43205

United States, Texas

University of Texas Southwestern Medical Center Oncology

Dallas, Texas, United States, 75235

Cook Children's Medical Center Oncology

Fort Worth, Texas, United States, 76104

United States, Washington

Seattle Childrens Hospital

Seattle, Washington, United States, 98105

France

Novartis Investigative Site

Bordeaux, Aquitaine, France, 33076

Novartis Investigative Site

Lille, France, 59000

Novartis Investigative Site

Paris Cedex, France, 75019

Novartis Investigative Site

Poitiers, France, 86021

Hungary

Novartis Investigative Site

Budapest, Hungary, 1094

Italy

Novartis Investigative Site

Genova, GE, Italy, 16147

Novartis Investigative Site

Monza, MB, Italy, 20900

Novartis Investigative Site

Padova, PD, Italy, 35128

Novartis Investigative Site

Torino, TO, Italy, 10126

Japan

Novartis Investigative Site

Yokohama-city, Kanagawa, Japan, 232-8555

Novartis Investigative Site

Sakyo Ku, Kyoto, Japan, 606 8507

Novartis Investigative Site

Shinjuku-ku, Tokyo, Japan, 160 8582

Novartis Investigative Site

Saitama, Japan, 330 8777

Novartis Investigative Site

Shizuoka, Japan, 420 8660

Korea, Republic of

Novartis Investigative Site

Seoul, Korea, Republic of, 03080

Novartis Investigative Site

Seoul, Korea, Republic of, 06351

Malaysia

Novartis Investigative Site

Kuala Lumpur, Malaysia, 50589

Netherlands

Novartis Investigative Site

Rotterdam, Netherlands, 3015 CE

Russian Federation

Novartis Investigative Site

Moscow, Russian Federation, 117198

Spain

Novartis Investigative Site

Madrid, Spain, 28009

Thailand

Novartis Investigative Site

Muang, Chiangmai, Thailand, 50200

Novartis Investigative Site

Bangkok, Thailand, 10330

Novartis Investigative Site

Bangkok, Thailand, 10700

Turkey

Novartis Investigative Site

Istanbul, Turkey, 34093

United Kingdom

Novartis Investigative Site

Sutton, Surrey, United Kingdom, SM2 5PT

Novartis Investigative Site

Bristol, United Kingdom, BS2 8BJ

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson B, Samis J, Aimone P, Allepuz A, Titorenko K, Sosothikul D. A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety. Blood Adv. 2021 Jul 27;5(14):2925-2934. doi: 10.1182/bloodadvances.2020003759.

Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia. Blood. 2019 Dec 5;134(23):2036-2045. doi: 10.1182/blood.2019000069.

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT01844765
• Other Study ID Numbers: CAMN107A2203; 2013-000200-41 ( EudraCT Number )
• First Posted: May 1, 2013
• Results First Posted: May 21, 2018
• Last Update Posted: April 22, 2021
• Last Verified: March 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes

Plan Description

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Tasigna; nilotinib treatment; chronic phase; Ph+ CML; accelerated phase; newly diagnosed Ph+ CML; pediatric; leukemia; leukemia, pediatric; leukemia, myleiod; leukemia, mylegenous, chronic; leukemia, mylegenous, accelerated; BCR-ABL positive; myeloproliferative disorder; bone marrow disease; hematologic diseases; neoplastic processes; imatinib; dasatinib; enzyme inhibitor; protein kinase inhibitor

Additional relevant MeSH terms:

Leukemia; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Myeloproliferative Disorders; Bone Marrow Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Nilotinib; Tyrosine Kinase Inhibitors; Protein Kinase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action